JP7097354B2 - Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 - Google Patents

Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 Download PDF

Info

Publication number
JP7097354B2
JP7097354B2 JP2019518301A JP2019518301A JP7097354B2 JP 7097354 B2 JP7097354 B2 JP 7097354B2 JP 2019518301 A JP2019518301 A JP 2019518301A JP 2019518301 A JP2019518301 A JP 2019518301A JP 7097354 B2 JP7097354 B2 JP 7097354B2
Authority
JP
Japan
Prior art keywords
fusion protein
seq
type
amino acid
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019518301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536439A5 (enExample
JP2019536439A (ja
Inventor
ラビンドラ クマール，
アシャ グリンバーグ，
ダイアン エス． サコ，
ロズリーヌ カストンギー，
Original Assignee
アクセルロン ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ インコーポレイテッド filed Critical アクセルロン ファーマ インコーポレイテッド
Publication of JP2019536439A publication Critical patent/JP2019536439A/ja
Publication of JP2019536439A5 publication Critical patent/JP2019536439A5/ja
Priority to JP2022102709A priority Critical patent/JP7504947B2/ja
Application granted granted Critical
Publication of JP7097354B2 publication Critical patent/JP7097354B2/ja
Priority to JP2024095366A priority patent/JP2024113195A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019518301A 2016-10-05 2017-10-05 Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 Active JP7097354B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022102709A JP7504947B2 (ja) 2016-10-05 2022-06-27 Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JP2024095366A JP2024113195A (ja) 2016-10-05 2024-06-12 Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404563P 2016-10-05 2016-10-05
US62/404,563 2016-10-05
PCT/US2017/055420 WO2018067873A2 (en) 2016-10-05 2017-10-05 Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022102709A Division JP7504947B2 (ja) 2016-10-05 2022-06-27 Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用

Publications (3)

Publication Number Publication Date
JP2019536439A JP2019536439A (ja) 2019-12-19
JP2019536439A5 JP2019536439A5 (enExample) 2020-11-12
JP7097354B2 true JP7097354B2 (ja) 2022-07-07

Family

ID=61831499

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019518301A Active JP7097354B2 (ja) 2016-10-05 2017-10-05 Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JP2022102709A Active JP7504947B2 (ja) 2016-10-05 2022-06-27 Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JP2024095366A Pending JP2024113195A (ja) 2016-10-05 2024-06-12 Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022102709A Active JP7504947B2 (ja) 2016-10-05 2022-06-27 Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JP2024095366A Pending JP2024113195A (ja) 2016-10-05 2024-06-12 Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用

Country Status (6)

Country Link
US (3) US11440949B2 (enExample)
EP (1) EP3522912A4 (enExample)
JP (3) JP7097354B2 (enExample)
AU (2) AU2017338915B2 (enExample)
CA (1) CA3039545A1 (enExample)
WO (1) WO2018067873A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
EP3788067A4 (en) 2018-05-03 2022-01-19 Acceleron Pharma Inc. NOVEL BINDERS OF TGFBETA SUPERFAMILY LIGANDS AND THEIR USES
AU2019262139A1 (en) * 2018-05-03 2020-11-26 Acceleron Pharma Inc. Multispecific binders of TGFβ-superfamily ligands and uses thereof
WO2020198293A1 (en) * 2019-03-25 2020-10-01 Northshore University Health System Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer
WO2021158695A1 (en) * 2020-02-03 2021-08-12 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
US20230183319A1 (en) * 2020-02-03 2023-06-15 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510198A (ja) 1997-05-16 2002-04-02 ザ プロクター アンド ギャンブル カンパニー スクリーニングのための骨形態形成タンパク質（ｂｍｐ）受容体複合体の使用
WO2016154601A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
JP2018513147A (ja) 2015-04-06 2018-05-24 アクセルロン ファーマ， インコーポレイテッド Ｔｇｆベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体およびその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
WO2010031168A1 (en) 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
KR20110047255A (ko) * 2008-09-26 2011-05-06 로슈 글리카트 아게 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체
CN103429620B (zh) * 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CN114699529A (zh) * 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510198A (ja) 1997-05-16 2002-04-02 ザ プロクター アンド ギャンブル カンパニー スクリーニングのための骨形態形成タンパク質（ｂｍｐ）受容体複合体の使用
WO2016154601A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
JP2018513147A (ja) 2015-04-06 2018-05-24 アクセルロン ファーマ， インコーポレイテッド Ｔｇｆベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体およびその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Dianne Sako et al.，Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB，THE JOURNAL OF BIOLOGICAL CHEMISTRY，2010年，VOL. 285、NO. 27，pp. 21037-21048
Karen Lavery et al.，BMP-2/4 and BMP-6/7 Differentially Utilize Cell Surface Receptors to Induce Osteoblastic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells，Journal of Biological Chemistry，2008年，Vol.283 No.30，pp. 20948-20958
Kengo Yamawaki et al.，The soluble form of BMPRIB is a novel therapeutic candidate for treating bone related disorders，Scientific Reports，2016年01月06日，Vol. 6、No. 18849

Also Published As

Publication number Publication date
AU2017338915A1 (en) 2019-04-18
WO2018067873A2 (en) 2018-04-12
JP2022137108A (ja) 2022-09-21
AU2025200960A1 (en) 2025-03-06
US12421295B2 (en) 2025-09-23
EP3522912A2 (en) 2019-08-14
JP7504947B2 (ja) 2024-06-24
CA3039545A1 (en) 2018-04-12
AU2017338915B2 (en) 2024-11-21
US11440949B2 (en) 2022-09-13
JP2024113195A (ja) 2024-08-21
JP2019536439A (ja) 2019-12-19
EP3522912A4 (en) 2020-10-14
US20250368720A1 (en) 2025-12-04
WO2018067873A3 (en) 2018-05-17
US20210147508A1 (en) 2021-05-20
US20230265161A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
JP7617962B2 (ja) バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JP7203807B2 (ja) シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
JP7504947B2 (ja) Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JP7037363B2 (ja) Ｔｇｆベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体およびその使用
JP7219705B2 (ja) ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
JP7159148B2 (ja) Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
JP2019527547A5 (enExample)
HK40078293A (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
HK40057061A (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
HK1248733B (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
EP3735418A1 (en) Single-arm co-receptor fusion proteins and uses thereof
HK1248732B (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
HK1252958B (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
HK40011178A (zh) 变体actriib蛋白及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201002

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220627

R150 Certificate of patent or registration of utility model

Ref document number: 7097354

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250